Quantification of Measurable Residual Disease in Adults with Acute Myeloid Leukemia

Testing for measurable residual disease (MRD) for patients in morphological complete remission from acute myeloid leukemia (AML) has the ability to better estimate risks of subsequent relapse and death. Increasing evidence suggests a benefit to deep DNA-sequencing based over currently performed clinical testing.
At the completion of this activity, learners will be able to:
1) compare the clinical utility of flow cytometric versus DNA-sequencing based measurable residual disease testing for patients in remission from AML prior to allogeneic transplantation.
2) evaluate the merits of single gene versus multigene panel testing for DNA-sequencing based measurable residual disease testing in AML.